We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Wegovy improved functional class vs. placebo at 1 year ...
ORLANDO, Fla. — Women with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without diabetes, derive the same benefit from the glucagon-like peptide 1 receptor agonist ...
Objective: To identify subgroups of heart failure patients who might benefit from biventricular pacing. Background: Cardiac resynchronization therapy (CRT) improves the quality of life, New York Heart ...
Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...
Adding ertugliflozin (Steglatro; Merck Sharp & Dohme), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to other therapies significantly reduces functional mitral regurgitation (MR) secondary to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback